2021
DOI: 10.1053/j.gastro.2020.05.098
|View full text |Cite
|
Sign up to set email alerts
|

Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study

Abstract: The pooled prevalence of digestive symptoms was 12%-15%, 9,10 with nausea or vomiting, diarrhea, and loss of appetite being the 3 most common symptoms. The geographical disparities also exist for the prevalence of GI symptoms and liver injury as reported by the American Gastroenterological Association Institute publication that digestive involvement was more prevalent outside China. 5,11 As for the association between GI involvement and the severity of COVID-19, according to our meta-analysis, 9 patients with … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
54
0
3

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 43 publications
(57 citation statements)
references
References 9 publications
0
54
0
3
Order By: Relevance
“…Despite the limitations of the study, famotidine was found to be associated with improved clinical outcomes, including lower in-hospital mortality, a lower composite of death and/or intubation, and lower levels of serum markers for serious disease [26]. On the contrary, a territory-wide retrospective cohort study in all COVID-19 patients from Hong Kong did not support any association between the use of famotidine and disease severity [27].…”
Section: Clinical Trials Of H 2 Receptor Antagonist Famotidine and Comentioning
confidence: 97%
“…Despite the limitations of the study, famotidine was found to be associated with improved clinical outcomes, including lower in-hospital mortality, a lower composite of death and/or intubation, and lower levels of serum markers for serious disease [26]. On the contrary, a territory-wide retrospective cohort study in all COVID-19 patients from Hong Kong did not support any association between the use of famotidine and disease severity [27].…”
Section: Clinical Trials Of H 2 Receptor Antagonist Famotidine and Comentioning
confidence: 97%
“…Five published articles [ 6 , 15 , 16 , 32 , 33 ] with 36,635 participants were included. The NOS scores of the four studies were ≥ 6 scores, which suggested moderate or high quality for the included studies.…”
Section: Resultsmentioning
confidence: 99%
“…Mather et al [ 15 ] agreed with their findings and shared similar opinions. On the other hand, Cheung et al [ 16 ] found no association between famotidine use and COVID-19 severity. Hence, it is necessary to assess effects of famotidine on improving the outcome of those suffered COVID-19 by a meta-analysis.…”
Section: Introductionmentioning
confidence: 99%
“…This study suggested that add-on famotidine therapy was independently associated with low incidence of adverse clinical outcomes. However, another recent retrospective cohort study of 952 patients in Hong Kong suggested that famotidine use was not associated with the severity of COVID-19 ( 4 ). Because of contradictory evidence, we conducted a meta-analysis to investigate the beneficial effects of famotidine on COVID-19.…”
mentioning
confidence: 99%
“…Finally, 3 observational studies ( 1 , 4 , 5 ) consisting of 3,450 participants were included. These included 2 high-quality studies and 1 medium-quality study.…”
mentioning
confidence: 99%